Justin Roberts
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Professor of Nutritional Physiology
Also affiliated: Dalhousie University (2013); University of Minnesota (2013–2014); Lehigh Valley Hospital-Pocono (2011–2013); University of Hertfordshire (2010–2016); University of Bedfordshire (2016); University of South Carolina (2006); Providence College (2020); Centre for Social Innovation (2026); New England College of Optometry (2020); Good Samaritan Medical Center (2015–2016); Somerset County Council (1998); Santa Clara Valley Medical Center (2012); Northwick Park Hospital (1997); Lancaster General Hospital (2014–2024); Providence VA Medical Center (2020); Qatar Orthopaedic and Sports Medicine Hospital (2016); Banner - University Medical Center Phoenix (2015); Danone (Netherlands) (2023–2026); Valley Medical Center (2012); Taunton & Somerset NHS Foundation Trust (1998); University of Pennsylvania Health System (2016–2024); Nutricia Research (Netherlands) (2023); Danone Nutricia Research (Netherlands) (2023); Anglia Ruskin University (2015–2026); Qatar University (2016); University of Pennsylvania (2011); Auburn University (2018)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Justin Roberts' research focuses on nutritional physiology, with a particular emphasis on performance and health outcomes in human subjects. His work has investigated the impact of diet and exercise on physiological parameters, including body composition and endurance capacity. Roberts has examined the accuracy of different methods for assessing body mass index and body composition, comparing self-reported data with measured values and evaluating bioelectrical impedance devices against dual-energy X-ray absorptiometry after specific dietary interventions.
His research also delves into specific populations and contexts, such as the nutritional requirements for ultra-endurance athletes and potential sex differences in physiological advantages for such sports. Roberts has explored the effects of interventions like probiotics and antioxidants on physiological markers in triathletes. With a substantial publication record (199 publications) and a high h-index (25), Roberts is recognized as a highly cited researcher. His collaborative network includes several colleagues from Arkansas State University, with whom he has co-authored multiple publications.
Metrics
- h-index: 25
- Publications: 199
- Citations: 2,308
Positions
-
Professor of Nutritional PhysiologyAnglia Ruskin University - Cambridge Campus ORCID
-
Professor of Nutritional Physiology publications 2023–2026Arkansas State University ORCID
Selected Publications
-
Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection (2026)
-
Construction of an arrayed CRISPRi library as a resource for essential gene function studies in Streptococcus mutans (2023)
-
Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors (2023)
Collaboration Network
Top Collaborators
- Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors
- Construction of an arrayed CRISPRi library as a resource for essential gene function studies in Streptococcus mutans
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors
- Construction of an arrayed CRISPRi library as a resource for essential gene function studies in Streptococcus mutans
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors
- Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors
- Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors
- Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors
- Construction of an arrayed CRISPRi library as a resource for essential gene function studies in Streptococcus mutans
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
- Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection
Similar Researchers
Based on overlapping research topics